• Skip to main content
  • Skip to header right navigation
  • Skip to site footer
  • About Us
  • Contact Us
  • Billing Portal
SPRINT® PNS System

SPR Therapeutics

SPRINT PNS System

  • Product
  • For Physicians
    • Clinical Outcomes & References
    • Implant Procedure Videos
    • Video Resources
    • SPRcare Reimbursement
    • Important Safety Information
    • MRI Safety Information
    • Promotional Marketing Toolkit
  • For Patients
    • Patient Stories
    • Patient Resources
    • Recursos para pacientes
    • MicroLead™ Safety
    • MRI Safety Information
  • Clinical Trials
  • News & Events
    • News
    • Events
    • Press Room
  • Careers

Opioid Concerns and Work Interference Cited as Top Reasons to Delay Knee Replacement Surgery

August 3, 2017

Opioid Concerns and Work Interference Cited as Top Reasons to Delay Knee Replacement Surgery

New survey shows patients often delay surgery for more than two years; 92% of respondents would seek surgeons who offer non-opioid pain management options

CLEVELAND, Ohio, Aug. 03, 2017 (GLOBE NEWSWIRE) — Patients in need of a total knee replacement (TKR) often delay surgery by two or more years because of concerns about the duration of postoperative pain, work interference, and the side effects opioids might have on their recovery and rehabilitation according to a new healthcare survey released today.

The survey explores patient perspectives and factors related to the decision to delay knee-replacement surgery, which is an increasingly common procedure.  In 2013 there were 727,000 primary and revision knee arthroplasty procedures in the U.S. and that number is projected to grow to 889,000 procedures by 2019, according to a Medtech Insight research report on U.S. surgical volumes.

“Regardless of pain level, gender, education or income, the majority of respondents delayed knee replacement surgery,” said Angeline Carlson, PhD, Adjunct Professor, Department of Pharmaceutical Care & Health Systems at the University of Minnesota.  “Results from this survey show that patients worry about the impact of surgery on their lives, have a very real concern about the ability to control pain during recovery, and possess an overwhelming desire to avoid using opioids to manage pain after surgery.”

654 surgical candidates suffering from knee osteoarthritis in the U.S. participated in the online survey, supported by SPR Therapeutics.  Highlights from the survey include:

  • More than half (54%) of respondents delayed a TKR for two or more years; 24% specifically cited concerns that postoperative pain and/or the side effects of opioids might extend their recovery and rehabilitation as reasons for delaying the procedure;
  • 92% of respondents said that a new pain management approach that reduced or eliminated the use of opioid-containing pain medications would be an important factor in their choice of the surgeon they would select to perform their surgery;
  • 66% said they would likely switch surgeons to obtain access to a non-opioid pain management approach;
  • 74% of respondents were more concerned about the pain they were likely to experience within the first several weeks following surgery compared to the pain they were likely to experience within the first three days following surgery.

“These results raise significant concerns because postponing surgery can often lead to deconditioning, weakening or lost function in muscles and ligaments and greater difficulty doing everyday activities,” said survey co-author Keith Berend, MD, Clinical Assistant Professor in the Department of Orthopaedics at The Ohio State University.  “Particularly here in Ohio, we face an epidemic of narcotic-related deaths, and we need access to innovative drug-free pain relief options that can carry patients through the rehabilitation period without opiates and help expedite their decision to have a surgery they should not postpone.  As one of the investigators currently using the SPRINT PNS System in clinical trials, I’m eager to offer it to my patients undergoing knee replacement surgery.”

The SPRINT PNS System includes a proprietary threadlike lead and a small, wearable stimulator patch.  The lead is placed percutaneously, or through the skin, and connects to the wearable stimulator, which activates peripheral nerves to achieve pain relief.

SPRINT was specifically designed to preferentially activate target nerve fibers, delivering sustained, significant pain relief without opioids, permanent implants or tissue destruction.  The FDA-cleared therapy was developed to address a wide spectrum of chronic and acute post-surgical pain conditions affecting millions worldwide.

“Opioids are routinely provided for several weeks to manage postoperative pain with approximately 20% of patients using them for 90 days or longer after surgery,” said Maria Bennett, SPR Therapeutics Founder, President and CEO.  “The results of this survey reinforce the need for alternative, non-narcotic pain relief therapies such as SPRINT, that could significantly reduce or even eliminate the use of opiates providing a much-needed medical advance for patients during the post-operative recovery period.”

Detailed results from the survey are published in a peer-reviewed article of Reconstructive Review, the official journal of the Joint Implant Surgery and Research Foundation.

About SPR Therapeutics 
SPR Therapeutics, LLC is a private company headquartered in Cleveland.  The company is commercializing its SPRINT™ technology which provides opioid-free, peripheral nerve stimulation for the relief of chronic and acute pain, and is advancing additional clinical trials to treat low back pain, neuropathic pain and pain following total knee replacement.  The SPR-patented SPRINT technology received FDA clearance for commercial use in the U.S.

SPR Contact: 
Mark Stultz
Senior Vice President
mstultz@sprtherapeutics.com
612.770.0390

FOR MEDIA QUERIES, Contact:
Tracey Sawicki
Frontcourt PR
tracey@frontcourtgroup.com
917.297.0574

Share this post:

Share on Twitter Share on Facebook Share on LinkedIn Share on SMS Share on Email
Category: News
Previous Post:SPR Therapeutics Awarded $6M Contract from the United States Department of Defense to Advance Non-opioid Pain Relief Therapy
Next Post:Patient Factors Affecting Surgeon Selection and the Decision to Delay Total Knee Arthroplasty

Sidebar

Archives

Recent News

Dr. Samir Sheth discusses how the SPRINT® PNS System has impacted his approach to treating patients with chronic head and neck pain

SPR Therapeutics Debuts Occipital Nerve Stimulation Data at ASRA 2022

A Discussion on Pain Management Options for Patients with Breast Cancer with Dr. Amitabh Gulati

Real-World Retrospective Review of Axial Neck Pain Relief Following Peripheral Nerve Stimulation of Cervical Medial Branch Nerves

Pain Medicine News Features SPRINT® PNS System Real-World Survey Outcomes

Tags

60-day percutaneous PNS acute pain Back Pain back pain treatment cancer pain chronic back pain Chronic Pain clinical study Dr. Mehul Desai drug-free EY award hip pain low back pain medial branch Neuromodulation Non-opioid oncological pain opioid alternative Pain pain appointment pain physician pain relief pain treatment Patients Patient Story peripheral nerve stimulation permanent PNS implant phantom limb pain PNS PNS training post-amputation pain Press release radiofrequency ablation recondition CNS reduced opioids research Research study residual limb pain RFA Shoulder Pain SPRINT PNS SPRINT PNS System temporary pns Training lab webinar
SPRINT® PNS System

22901 Millcreek Blvd, Suite 500
Cleveland, OH 44122
(844) 378-9108 Phone
(216) 803-0777 Fax

Top Work Places 2022

Quick Links

  • Product
  • For Physicians
  • For Patients
  • Clinical Trials
  • News & Events
  • Careers
  • About Us
  • Contact Us

Legal Links

  • Privacy Statement
  • Terms of Use
  • CPRA Requests
  • Important Safety Information
  • Compliance
  • FCOI Policy
  • Product Terms & Conditions
  • Patent Information

Recent News Headlines

Dr. Samir Sheth discusses how the SPRINT® PNS System has impacted his approach to treating patients with chronic head and neck pain

NANS 26th Annual Meeting – Las Vegas, NV

Sprint Regional Lab – Jacksonville

Sprint Regional Lab – Chicago

The SPRINT PNS System is indicated for up to 60 days for: (i) Symptomatic relief of chronic, intractable pain, post-surgical and post-traumatic acute pain; (ii) Symptomatic relief of post-traumatic pain; and (iii) Symptomatic relief of post-operative pain. The SPRINT PNS System is not intended to treat pain in the region innervated by the cranial and facial nerves. Physicians should use their best judgment when deciding when to use the SPRINT PNS System. For more information see the SPRINT PNS System IFU. Most common adverse events are skin irritation and erythema. Results may vary. Rx only.

View References for support of all claims.

The SPRINT® PNS System, MicroLead™, OnePass Introducer™, Rethink Your Pain Strategy™, Outsmart Pain™, Sustained Pain Relief Starts Here™, Life. Get Back to It.™ and SPR® are registered or common law trademarks of SPR Therapeutics, Inc.


Copyright © 2023 SPR Therapeutics. All Rights Reserved.

This website is intended only for US and Canadian residents 18 years of age and older. By clicking “Accept”, you consent to the use of ALL the cookies.
Cookie settingsACCEPT
Manage consent

Privacy Overview

This website uses cookies to improve your experience while you navigate through the website. Out of these cookies, the cookies that are categorized as necessary are stored on your browser as they are essential for the working of basic functionalities of the website. We also use third-party cookies that help us analyze and understand how you use this website. These cookies will be stored in your browser only with your consent. You also have the option to opt-out of these cookies. But opting out of some of these cookies may have an effect on your browsing experience.
Necessary
Always Enabled
Necessary cookies are absolutely essential for the website to function properly. These cookies ensure basic functionalities and security features of the website, anonymously.
CookieDurationDescription
cookielawinfo-checkbox-analytics11 monthsThis cookie is set by GDPR Cookie Consent plugin. The cookie is used to store the user consent for the cookies in the category "Analytics".
cookielawinfo-checkbox-functional11 monthsThe cookie is set by GDPR cookie consent to record the user consent for the cookies in the category "Functional".
cookielawinfo-checkbox-necessary11 monthsThis cookie is set by GDPR Cookie Consent plugin. The cookies is used to store the user consent for the cookies in the category "Necessary".
cookielawinfo-checkbox-others11 monthsThis cookie is set by GDPR Cookie Consent plugin. The cookie is used to store the user consent for the cookies in the category "Other.
cookielawinfo-checkbox-performance11 monthsThis cookie is set by GDPR Cookie Consent plugin. The cookie is used to store the user consent for the cookies in the category "Performance".
viewed_cookie_policy11 monthsThe cookie is set by the GDPR Cookie Consent plugin and is used to store whether or not user has consented to the use of cookies. It does not store any personal data.
Functional
Functional cookies help to perform certain functionalities like sharing the content of the website on social media platforms, collect feedbacks, and other third-party features.
Performance
Performance cookies are used to understand and analyze the key performance indexes of the website which helps in delivering a better user experience for the visitors.
Analytics
Analytical cookies are used to understand how visitors interact with the website. These cookies help provide information on metrics the number of visitors, bounce rate, traffic source, etc.
Advertisement
Advertisement cookies are used to provide visitors with relevant ads and marketing campaigns. These cookies track visitors across websites and collect information to provide customized ads.
Others
Other uncategorized cookies are those that are being analyzed and have not been classified into a category as yet.
Save & Accept
Powered by CookieYes Logo